Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is currently in the preclinical stage of development, with plans to enter the clinic with its lead candidate in 2027. The company maintains a strong financial position with over $500 million in cash, enough to fund operations until at least 2029. Recent updates on the company's pipeline have shown promising data, including a human half-life of approximately 3-4 days for their lead candidate SEP-479 and potential for their MRGPRX2 NAM, SEP-631, in multiple indications. With a diverse and robust pipeline and a strong cash position, investors should keep an eye on the potential for upside should SEP-479 continue to show positive results in upcoming trials.

Bears say

Septerna is a clinical-stage biotechnology company that operates in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. While its proprietary Native Complex Platform shows potential for GPCR therapies, the outlook for the company remains negative due to the lack of diverse product revenue and high risks associated with phase 1 trials, developmental milestones, and competition in target markets, resulting in a limited price objective of $60 per share by mid-2027.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Sep 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.